SEC Form 25-NSE filed by Reviva Pharmaceuticals Holdings Inc.

12/12/25 4:53:15 PM ET

$RVPH

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $RVPH alert in real time by email

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

UNITED STATES

OMB APPROVAL

OMB Number:		3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:		1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-38634

Issuer:	REVIVA PHARMACEUTICALS HOLDINGS, INC.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	10080 N Wolfe Rd
	Suite SW3-200
	Cupertino	CALIFORNIA	95014
Telephone number:				(408) 501-8881

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Warrants expiring 12/14/2025

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2025-12-12	By	Jennifer Fainer		CDO Analyst
Date		Name		Title

¹	Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $RVPH alert in real time by email

Date

Price Target

Rating

Analyst

9/29/2025

$2.00

Buy

Chardan Capital Markets

9/20/2023

$12.00

Buy

ROTH MKM

6/8/2023

$17.00

Speculative Buy

The Benchmark Company

1/24/2022

$10.00

Buy

HC Wainwright & Co.

7/26/2021

$10.00

Buy

Maxim Group

SEC Form 25-NSE filed by Reviva Pharmaceuticals Holdings Inc.

12/12/25 4:53:15 PM ET

$RVPH

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $RVPH alert in real time by email

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

UNITED STATES

OMB APPROVAL

OMB Number:		3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:		1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-38634

Issuer:	REVIVA PHARMACEUTICALS HOLDINGS, INC.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	10080 N Wolfe Rd
	Suite SW3-200
	Cupertino	CALIFORNIA	95014
Telephone number:				(408) 501-8881

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Warrants expiring 12/14/2025

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

2025-12-12	By	Jennifer Fainer		CDO Analyst
Date		Name		Title

¹	Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $RVPH alert in real time by email

Date

Price Target

Rating

Analyst

9/29/2025

$2.00

Buy

Chardan Capital Markets

9/20/2023

$12.00

Buy

ROTH MKM

6/8/2023

$17.00

Speculative Buy

The Benchmark Company

1/24/2022

$10.00

Buy

HC Wainwright & Co.

7/26/2021

$10.00

Buy

Maxim Group

SEC Form 25-NSE filed by Reviva Pharmaceuticals Holdings Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$RVPH

SEC Form 25-NSE filed by Reviva Pharmaceuticals Holdings Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$RVPH

$RVPH
Press Releases

Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia

Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum

Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia

$RVPH
SEC Filings

Reviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13D/A filed by Reviva Pharmaceuticals Holdings Inc.